Overview

MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

Status:
Recruiting
Trial end date:
2022-02-25
Target enrollment:
Participant gender:
Summary
To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Xiaojun Chen
Treatments:
Dydrogesterone
Medroxyprogesterone
Medroxyprogesterone Acetate